• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23734 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Penn Medicine Center for Evidence-based Practice (CEP) Risk factors for complications of percutaneous coronary intervention
2014     Penn Medicine Center for Evidence-based Practice (CEP) Risk factors for high resource utilization in patients with sickle cell disease
2011     Penn Medicine Center for Evidence-based Practice (CEP) Risk factors for hospital readmission
2018     Health Information and Quality Authority (HIQA) Risk factors for inclusion as criteria within the clinical guideline on risk classification during pregnancy: a modified Delphi study
2018     Penn Medicine Center for Evidence-based Practice (CEP) Risk Factors for Surgical Site Infection and Infection Prevention in Elective Spine Surgery
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Risk factors to consider for extended anticoagulant therapy: a review of guidelines
2019     Health Information and Quality Authority (HIQA) Risk in pregnancy — systematic review of economic literature.
1996     Health Council of the Netherlands Gezondheidsraad (GR) Risk is more than just a number
2005     Alberta Heritage Foundation for Medical Research (AHFMR) Risk management for health technology assessment programs
2015     NIHR Health Services and Delivery Research programme Risk modelling for quality improvement in the critically ill: making best use of routinely available data
2003     Centre for Clinical Effectiveness (CCE) Risk of cerebral herniation due to lumbar puncture in children with suspected meningitis
2000     Centre for Clinical Effectiveness (CCE) Risk of infection in patients with femoral fractures who experience delays in surgery of more than 12 hours
1997     Health Council of the Netherlands Gezondheidsraad (GR) Risk profiles for HIV-positive individuals
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2020     NIHR Health Technology Assessment programme Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT
2013     HAYES, Inc. Risk-reducing (prophylactic) mastectomy
2021     NIHR Public Health Research (PHR) programme RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2016     NIHR Health Technology Assessment programme Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records
2013     The HTA Center of the Stockholm County Council/Gotland Risks associated with planned home delivery for nulliparous women
2005     Health Council of the Netherlands Gezondheidsraad (GR) Risks of alcohol consumption related to conception, pregnancy and breastfeeding
2007     Health Council of the Netherlands Gezondheidsraad (GR) Risks of exposure to ionising radiation
2000     Health Council of the Netherlands Gezondheidsraad (GR) Risks of folic acid fortification
1996     Conseil d'Evaluation des Technologies de la Santé du Quebec (CETS) Risks of occupational anaesthetic gas exposure for the pregnant woman and the fetus - systematic review
2009     NIHR Horizon Scanning Centre (NIHR HSC) Risperidone long-acting injection (Risperdal Consta) for prevention of recurrent episodes in bipolar 1 disorder
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2009     HAYES, Inc. Rituxan (Genentech Inc. and Biogen Idec Inc.) for Graft-Versus-Host Disease
2011     HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for Chronic Lymphocytic Leukemia(CLL)
2010     HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for multiple sclerosis
2009     HAYES, Inc. Rituxan (rituximab) (Genentech Inc. and Biogen Idec Inc.) for rheumatoid arthritis refractory to methotrexate and/or tumor necrosis factor (TNF) inhibitors
2010     HAYES, Inc. Rituxan (Rituximab) (Genentech Inc. and Biogen Idec Inc.) for systemic lupus erythematosus
2000     Alberta Heritage Foundation for Medical Research (AHFMR) Rituxan(R) (rituximab)
2004     NIHR Health Technology Assessment programme Rituximab (MabThera(R)) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation
2011     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2011     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for chronic lymphocytic leukaemia
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (Mabthera) for non-Hodgkin’s lymphoma – first line maintenance therapy
2003     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for rheumatoid arthritis - horizon scanning review
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rituximab (MabThera®)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia
2009     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (Rituxan/MabThera) for the first- and second-line treatment of chronic lymphocytic leukaemia
2002     NIHR Health Technology Assessment programme Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab biosimilars
2004     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab for 1st line low-grade non-Hodgkin's lymphoma - horizon scanning review
2002     NIHR Horizon Scanning Centre (NIHR HSC) Rituximab for aggressive B-cell lymphoma - horizon scanning review
2003     Quality Improvement Scotland (NHS QIS ) Rituximab for aggressive non-Hodgkin's lymphoma
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for granulomatosis with polyangiitis or microscopic polyangiitis: a review of the clinical and cost-effectiveness
2010     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for non-hodgkin's lymphoma: a review of the clinical and cost- effectiveness and guidelines
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for rheumatoid arthritis
2010     NIHR Health Technology Assessment programme Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
2011     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 226
2009     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of chronic lymphocytic leukaemia. NICE technology appraisal guidance 174
2012     National Institute for Health and Care Excellence (NICE) Rituximab for the first-line treatment of stage III-IV follicular lymphoma. NICE technology appraisal guidance 243
2012     NIHR Health Technology Assessment programme Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation
2009     NIHR Health Technology Assessment programme Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
2006     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of follicular lymphoma
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Rituximab for the treatment of primary membranous nephropathy
2010     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. NICE technology appraisal guidance 193
2009     NIHR Health Technology Assessment programme Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2008     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma
2008     National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 137
2010     NIHR Health Technology Assessment programme Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
2009     NIHR Health Technology Assessment programme Rituximab for the treatment of rheumatoid arthritis
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab for the treatment of rheumatoid arthritis
2008     Institute for Clinical Effectiveness and Health Policy (IECS) Rituximab for the treatment of rheumatoid arthritis
2007     Quality Improvement Scotland (NHS QIS ) Rituximab for the treatment of rheumatoid arthritis
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2002     Blue Cross Blue Shield Association (BCBS) Rituximab for treatment of intermediate and aggressive B-cell non-Hodgkin's lymphomas
2013     NIHR Health Technology Assessment programme Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis
2014     National Institute for Health and Care Excellence (NICE) Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis. NICE technology appraisal guidance 308
2007     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Bay 59-7939) for the prevention of venous thromboembolism (VTE) after major orthopaedic surgery: horizon scanning technology briefing
2014     Canadian Agency for Drugs and Technologies in Health (CADTH) Rivaroxaban (Xarelto- Bayer Inc.) new Indication: pulmonary embolism
2011     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for acute coronary syndrome
2010     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for prevention of venous thromboembolism in medically ill patients
2009     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for stroke prevention in atrial fibrillation
2010     NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for venous thromboembolism
2015     National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome. NICE technology appraisal guidance 335
2019     National Institute for Health and Care Excellence (NICE) Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. NICE technology appraisal guidance 607
2011     NIHR Health Technology Assessment programme Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation: a single technology appraisal
2012     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. NICE technology appraisal guidance 256
2009     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. NICE technology appraisal guidance 170
2009     NIHR Health Technology Assessment programme Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
2012     National Institute for Health and Care Excellence (NICE) Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261
2012     NIHR Health Technology Assessment programme Rivaroxaban for the treatment of deep vein thrombosis and secondary prevention of venous thromboembolism
2013     National Institute for Health and Care Excellence (NICE) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
1998     Wessex Institute for Health Research and Development (WIHRD) Rivastigmine (Exelon TM) in the treatment of senile dementia of the Alzheimer type (SDAT)
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2024     Health Technology Wales (HTW) Robot-assisted benign gynaecological surgery
2010     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Robot-assisted endoscopic thyroidectomy
2022     Agency for Care Effectiveness (ACE) Robot-assisted endovascular intervention systems for coronary artery disease and other vascular diseases
2018     National Institute for Health and Care Excellence (NICE) Robot-assisted kidney transplant. NICE interventional procedures guidance 609
2008     Institute for Clinical Effectiveness and Health Policy (IECS) Robot-assisted surgery in prostate cancer
2019     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Robot-assisted surgery in thoracic and visceral indications
2019     European Network for Health Technology Assessment (EUnetHTA) Robot-assisted surgery in thoracic and visceral indications
2023     Austrian Institute for Health Technology Assessment (AIHTA) Robot-assisted surgery in thoracic and visceral indications – Update 2023
2007     Andalusian Health Technology Assessment Area (AETSA) Robot-assisted surgery using da Vinci robot telemanipulation in prostatectomy
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Robot-assisted surgery versus open surgery and laparoscopic surgery: clinical and cost-effectiveness analyses
2009     Belgian Health Care Knowledge Centre (KCE) Robot-assisted surgery: health technology assessment
2008     Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Robot-assisted surgery: the da Vinci robot